TIDMPRTC
PureTech Health PLC
08 March 2022
8 March 2022
PureTech Health plc
PureTech Founded Entity Akili Named to Fast Company's Annual
List of the World's 50 Most Innovative Companies for 2022
Akili, the maker of EndeavorRx (R), the first-and-only
FDA-cleared prescription video game treatment, joins the ranks of
Canva, Microsoft, SpaceX, and more
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company noted that its
Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading
digital medicine company pioneering the development of cognitive
treatments through game-changing technologies, today announced it
has been named to Fast Company's prestigious list of the World's
Most Innovative Companies for 2022. This year's list honors
businesses that are making the biggest impacts on their industries
and culture as a whole and thriving in today's ever-changing
world.
Akili is developing digital prescription treatments to improve
cognition, developed through a unique collaboration of cognitive
neuroscientists and entertainment and technology designers. The
Akili platform represents a fundamental paradigm shift where
technology is the medicine, designed to target neural networks
critical to cognitive function. The company aims to transform the
user-friendly experiences of digital therapeutics into
clinically-validated treatments for cognitive functions that are
designed to be indistinguishable from high-end entertainment
experiences. With this approach, in June 2020, Akili introduced the
first prescription video game treatment for any disease cleared by
the U.S. Food and Drug Administration (FDA) - a treatment focusing
on attention function for children with
attention-deficit/hyperactivity disorder (ADHD). In addition, Akili
is progressing research across a diverse set of indications,
including treatments for cognitive impairments associated with
major depressive disorder, autism spectrum disorder and multiple
sclerosis.
The full text of the announcement from Akili is as follows:
Akili Named to Fast Company's Annual List of the World's 50 Most
Innovative Companies for 2022
Maker of the first-and-only FDA-cleared prescription video game
treatment joins the ranks of Canva, Microsoft, SpaceX, and more
BOSTON, Mass. March 8, 2022 - Akili Interactive Labs, Inc.
("Akili"), a leading digital medicine company pioneering the
development of cognitive treatments through game-changing
technologies, today announced it has been named to Fast Company's
prestigious list of the World's Most Innovative Companies for
2022.
This year's list honors businesses that are making the biggest
impacts on their industries and culture as a whole and thriving in
today's ever-changing world. The companies included have been
recognized for their contributions to some of the most inspiring
accomplishments of the 21st century. To select the honorees, Fast
Company's editors and writers sought out the most groundbreaking
businesses across the globe.
"We are honored to be recognized by Fast Company as one of the
world's most innovative companies. Akili was founded with a vision
to create treatments that are both effective and enjoyable,
ushering in a new category of medicine," said Eddie Martucci,
Co-Founder and Chief Executive Officer of Akili. "We're committed
to continuing to challenge the status quo by leveraging innovative
technology to positively impact the millions of people living with
cognitive impairments, as we reimagine what medicine should feel
like."
The World's Most Innovative Companies is Fast Company's
signature franchise and one of its most highly anticipated
editorial efforts of the year. It provides both a snapshot and a
road map for the future of innovation across the most dynamic
sectors of the economy.
"The world's most innovative companies play an essential role in
addressing the most pressing issues facing society, whether they're
fighting climate change by spurring decarbonization efforts,
ameliorating the strain on supply chains, or helping us reconnect
with one another over shared passions," said Fast Company Deputy
Editor David Lidsky.
Founded in 2011, Akili is developing digital prescription
treatments to improve cognition, developed through a unique
collaboration of cognitive neuroscientists and entertainment and
technology designers. The Akili platform represents a fundamental
paradigm shift where technology is the medicine, designed to target
neural networks critical to cognitive function. The company aims to
transform the user-friendly experiences of digital therapeutics
into clinically-validated treatments for cognitive functions that
are designed to be indistinguishable from high-end entertainment
experiences. With this approach, in June 2020 Akili introduced the
first prescription video game treatment for any disease cleared by
the U.S. Food and Drug Administration (FDA) - a treatment focusing
on attention function for children with
attention-deficit/hyperactivity disorder (ADHD). In addition, Akili
is progressing research across a diverse set of indications,
including treatments for cognitive impairments associated with
major depressive disorder, autism spectrum disorder and multiple
sclerosis.
On January 26, 2022, Akili entered into a definitive agreement
to become publicly traded via a merger with Social Capital Suvretta
Holdings Corp. I (Nasdaq: DNAA), a special purpose acquisition
company. The transaction is expected to close in mid-2022, subject
to satisfaction of the closing conditions, after which Akili will
be listed on the Nasdaq stock market under the new ticker symbol
"AKLI."
For the second year in a row, to coincide with the issue launch,
Fast Company will host its Most Innovative Companies Summit on
April 26-27. The virtual, multi-day summit celebrates the Most
Innovative Companies in business and provides an early look at
major business trends and an inside look at what it takes to
innovate in 2022. Fast Company's Most Innovative Companies issue
(March/April 2022) is available online, as well as in-app form via
iTunes, and on newsstands beginning March 15.
About Fast Company
Fast Company is the only media brand fully dedicated to the
vital intersection of business, innovation, and design, engaging
the most influential leaders, companies, and thinkers on the future
of business. Headquartered in New York City, Fast Company is
published by Mansueto Ventures LLC, along with our sister
publication Inc., and can be found online at
www.fastcompany.com.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Our approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine - medicine that is validated through
clinical trials like a drug or medical device, but experienced like
entertainment. Akili's platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili's belief that
effective medicine can also be fun and engaging, Akili's products
are delivered through captivating action video game experiences.
For more information, please visit www.akiliinteractive.com.
Additional Information and Where to Find It
In connection with the proposed business combination transaction
between Social Capital Suvretta Holdings Corp. I ("SCS") and Akili,
SCS filed a registration statement on Form S-4 (as amended, the
"Registration Statement") with the SEC on February 14, 2022, which
includes a preliminary prospectus and proxy statement of SCS,
referred to as a proxy statement/prospectus. The Registration
Statement has not yet become effective. When available, a final
proxy statement/prospectus will be sent to all SCS shareholders.
SCS will also file other documents regarding the proposed
transaction with the SEC. SHAREHOLDERS OF SCS ARE ADVISED TO READ
THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ALL
OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC
IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
Shareholders will be able to obtain free copies of the Registration
Statement, the proxy statement/prospectus and all other relevant
documents filed or that will be filed with the SEC by SCS (when
available) through the website maintained by the SEC at
http://www.sec.gov.
The documents filed by SCS with the SEC also may be obtained
free of charge at SCS's website at
https://socialcapitalsuvrettaholdings.com/dnaa or upon written
request to 2850 W. Horizon Ridge Parkway, Suite 200, Henderson, NV
89052.
Participants in the Solicitation
SCS and Akili and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from SCS's shareholders in connection with the proposed
transaction. A list of the names of such directors and executive
officers and information regarding their interests in the proposed
transaction between Akili and SCS are contained in the proxy
statement/prospectus. You may obtain free copies of these documents
as described in the preceding paragraph.
No Offer or Solicitation
This communication shall not constitute a solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed transaction. This communication shall
not constitute an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any states or jurisdictions in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of such state or jurisdiction. No offering of
securities shall be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act or an
exemption therefrom. This press release may be deemed to be
solicitation material in respect of the proposed transactions
contemplated by the proposed business combination between Akili and
SCS.
Forward-Looking Statements
This communication may contain certain forward-looking
statements within the meaning of the federal securities laws with
respect to the proposed transaction between Akili and SCS. These
forward-looking statements generally are identified by the words
"believe," "project," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would," "will be," "will continue," "will likely result,"
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this communication, including but not
limited to: (i) the risk that the proposed transaction may not be
completed in a timely manner or at all, which may adversely affect
the price of SCS's securities, (ii) the risk that the proposed
transaction may not be completed by SCS's business combination
deadline and the potential failure to obtain an extension of the
business combination deadline if sought by SCS, (iii) the failure
to satisfy the conditions to the consummation of the proposed
transaction, including the adoption of the Merger Agreement by the
shareholders of SCS and the satisfaction of the minimum cash
condition, (iv) the lack of a third party valuation in determining
whether or not to pursue the proposed transaction, (v) the
inability to complete the PIPE Investment, (vi) the occurrence of
any event, change or other circumstance that could give rise to the
termination of the Merger Agreement, (vii) the effect of the
announcement or pendency of the transaction on Akili's business
relationships, operating results, and business generally, (viii)
risks that the proposed transaction disrupts current plans and
operations of Akili or diverts management's attention from Akili's
ongoing business operations and potential difficulties in Akili
employee retention as a result of the announcement and consummation
of the proposed transaction, (ix) the outcome of any legal
proceedings that may be instituted against Akili or against SCS
related to the Merger Agreement or the proposed transaction, (x)
the ability to maintain the listing of SCS's securities on a
national securities exchange, (xi) the price of SCS's securities
may be volatile due to a variety of factors, including changes in
the competitive and highly regulated industries in which SCS plans
to operate or Akili operates, variations in operating performance
across competitors, changes in laws and regulations affecting SCS's
or Akili's business, and changes in the combined capital structure,
(xii) the ability to implement business plans, forecasts, and other
expectations after the completion of the proposed transaction, and
identify and realize additional opportunities, (xiii) the ability
of Akili to successfully commercialize EndeavorRx(R) and continue
to advance its clinical development pipeline, (xiv) the ability to
recognize the anticipated benefits of the proposed transaction,
which may be affected by, among other things, competition, the
ability of the combined company to grow and manage growth
profitably, maintain relationships with customers and suppliers and
retain its management and key employees, (xv) the evolution of the
markets in which Akili competes, (xvi) the ability of Akili to
defend its intellectual property and satisfy regulatory
requirements, (xvii) the costs related to the proposed transaction,
(xviii) the impact of the COVID-19 pandemic on Akili's business,
(xix) Akili's expectations regarding its market opportunities and
(xx) the risk of downturns and a changing regulatory landscape in
the highly competitive industry in which Akili operates. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the "Risk Factors" section of SCS's
registration on Form S-1 (File Nos. 333-256723 and 333-257543),
SCS's quarterly report on Form 10-Q for the quarter ended September
30, 2021 filed with the SEC on November 15, 2021, the Registration
Statement on Form S-4, including those under "Risk Factors"
therein, and other documents filed by SCS from time to time with
the SEC. These filings identify and address other important risks
and uncertainties that could cause actual events and results to
differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and Akili and SCS assume no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise. Neither Akili nor SCS gives any assurance that either
Akili or SCS, or the combined company, will achieve its
expectations.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 25 therapeutics and therapeutic
candidates, including two that have received both U.S. FDA
clearance and European marketing authorization, as of the date of
PureTech's most recently filed Half Year Report and corresponding
Form 6-K. All of the underlying programs and platforms that
resulted in this pipeline of therapeutic candidates were initially
identified or discovered and then advanced by the PureTech team
through key validation points based on the Company's unique
insights into the biology of the brain, immune and gut, or BIG,
systems and the interface between those systems, referred to as the
BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those statements that relate to expectations
around EndeavorRx , the proposed business combination agreement
between Akili and Social Capital Suvretta Holdings Corp. I (Nasdaq:
DNAA) or matters related thereto, t he competitive environment in
which Akili operates, and Akili and PureTech's future prospects,
development plans, and strategies. The forward-looking statements
are based on current expectations and are subject to known and
unknown risks, uncertainties and other important factors that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2020 filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKZGGFMRVGZZM
(END) Dow Jones Newswires
March 08, 2022 07:05 ET (12:05 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024